Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature

References

• Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7(4):322–337.
   PubMed Web of Science ®Google Scholar
• Eglinton TW, Barclay ML, Gearry RB, et al. The spectrum of perianal Crohn’s disease in a population-based cohort. Dis Colon Rectum. Forthcoming.
   Web of Science ®Google Scholar
• Schwartz D, Loftus E Jr., Tremaine W, et al. The natural history of fistulizing Crohn’s disease in Olmsted county, Minnesota. Gastroenterology. 2002;122(4):875–880.
   PubMed Web of Science ®Google Scholar
• Attauabi M, Zhao M, Bendtsen F, et al. Systematic review with meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease course of inflammatory bowel diseases. Inflamm Bowel Dis. Forthcoming. DOI:10.1093/ibd/izaa167
   Web of Science ®Google Scholar
• Beaugerie L, Seksik P, Nion-Larmurier I, et al. Predictors of Crohn’s disease. Gastroenterology. 2006;130(3):650–656.
   PubMed Web of Science ®Google Scholar
• Loly C, Belaiche J, Louis E. Predictors of Crohn’s disease. Scand J Gastroenterol. 2008;43(8):948–954.
   PubMed Web of Science ®Google Scholar
• Zhao M, Lo BZS, Vester-Andersen MK, et al. A 10-year follow-up study of the natural history of perianal Crohn’s disease in a Danish population-based inception cohort. Inflamm Bowel Dis. 2019;25(7):1227–1236.
   PubMed Web of Science ®Google Scholar
• Gecse KB, Bemelman W, Kamm MA, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63(9):1381–1392.
   PubMed Web of Science ®Google Scholar
• Steinhart A, Panaccione R, Targownik L, et al. Clinical practice guideline for the medical management of perianal fistulizing Crohn’s disease: the Toronto consensus. Inflamm Bowel Dis. 2019;25(1):1–13.
   PubMed Web of Science ®Google Scholar
• Lee M, Parker C, Taylor S, et al. Efficacy of medical therapies for fistulizing Crohn’s disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(12):1879–1892.
   PubMed Web of Science ®Google Scholar
• Sands B, Gasink C, Jacobstein D, et al. Fistula healing in pivotal studies of ustekinumab in Crohn’s disease. Gastroenterology. 2017;152(5):S185.
   Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Available from: www.handbook.cochrane.org
   Google Scholar
• Ryan R, Synnot A, Prictor M, et al. Cochrane Consumers and Communication Group Data extraction template for included studies. CCCG. La Trobe University, Melbourne. 2016 [cited 2016 Nov 29]. Available from: http://cccrg.cochrane.org/author-resources
   Google Scholar
• Ga Wells B, O’Connell D, Peterson J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [cited 2020 May 23]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
   Google Scholar
• Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease–the McGill experience. J Crohns Colitis. 2014;8(11):1516–1522.
   PubMed Web of Science ®Google Scholar
• Khorrami S, Ginard D, Marín-Jiménez I, et al. Ustekinumab for the treatment of refractory Crohn’s disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22(7):1662–1669.
   PubMed Web of Science ®Google Scholar
• Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14(2):242–250.
   PubMed Web of Science ®Google Scholar
• Ma C, Fedorak R, Kaplan G, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45(9):1232–1243.
   PubMed Web of Science ®Google Scholar
• Tsistrakis S, Oikonomou I. Real-life data on the use of ustekinumab for the treatment of fistulas in patients with Crohn’s disease. Am J Gastroenterol. 2017;112:S361.
   Web of Science ®Google Scholar
• Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, et al. Ustekinumab for Crohn’s Disease: results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. J Crohns Colitis. 2020;14(1):33–45.
   PubMed Web of Science ®Google Scholar
• Chapuis-Biron C, Kirchgesner J, Pariente B, et al. Ustekinumab for perianal Crohn’s disease: the BioLAP Multicenter Study From the GETAID. Am J Gastroenterol. 2020;115(11):1812–1820.
   PubMed Web of Science ®Google Scholar
• Attauabi M, Burisch J, Seidelin JB. Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: a double-center cohort study. Inflamm Bowel Dis. 2020. DOI:10.1093/ibd/izaa297
   Google Scholar
• Clinicaltrials.gov. U.S National Library of Medicine. [cited 2020 Jul 13] Available from: https://clinicaltrials.gov/ct2/results?cond=&term=ustekinumab&cntry=&state=&city=&dist=
   Google Scholar
• Sands B, Anderson F, Bernstein C, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–885.
   PubMed Web of Science ®Google Scholar
• Colombel J–F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132(1):52–65.
   PubMed Web of Science ®Google Scholar
• Schreiber A, Lawrance I, Thomsen O, et al. Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011;33(2):185–189.
   PubMed Web of Science ®Google Scholar
• Ng SC, Plamondon S, Gupta A, et al. Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn’s fistulas. Aliment Pharmacol Ther. Forthcoming. DOI:10.1111/j.1365-2036.2009.04088.x
   Web of Science ®Google Scholar
• Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn’s disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. Forthcoming. DOI:10.1111/j.1572-0241.2008.02175.x
   Web of Science ®Google Scholar
• Lichtiger S, Binion DG, Wolf DC, et al. The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohns disease who failed prior infliximab therapy. Aliment Pharmacol Ther. Forthcoming. DOI:10.1111/j.1365-2036.2010.04466.x
   Web of Science ®Google Scholar
• Mahadev S, Young JM, Selby W, et al. Quality of life in perianal Crohn’s disease: what do patients consider important? Dis Colon Rectum. Forthcoming. DOI:10.1007/DCR.0b013e3182099d9e
   Web of Science ®Google Scholar